Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 7
2003 4
2004 5
2005 7
2006 10
2007 2
2008 4
2009 4
2010 5
2011 3
2012 5
2013 11
2014 14
2015 16
2016 4
2017 7
2018 5
2019 6
2020 5
2021 5
2022 5
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

127 results

Results by year

Filters applied: . Clear all
Page 1
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.
Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Oki Y, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Chen R, Ramchandren R, Zinzani PL, Cunningham D, Rosta A, Josephson NC, Song E, Sachs J, Liu R, Jolin HA, Huebner D, Radford J; ECHELON-1 Study Group. Connors JM, et al. Among authors: smolewski p. N Engl J Med. 2018 Jan 25;378(4):331-344. doi: 10.1056/NEJMoa1708984. Epub 2017 Dec 10. N Engl J Med. 2018. PMID: 29224502 Free PMC article. Clinical Trial.
Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma.
Ansell SM, Radford J, Connors JM, Długosz-Danecka M, Kim WS, Gallamini A, Ramchandren R, Friedberg JW, Advani R, Hutchings M, Evens AM, Smolewski P, Savage KJ, Bartlett NL, Eom HS, Abramson JS, Dong C, Campana F, Fenton K, Puhlmann M, Straus DJ; ECHELON-1 Study Group. Ansell SM, et al. Among authors: smolewski p. N Engl J Med. 2022 Jul 28;387(4):310-320. doi: 10.1056/NEJMoa2206125. Epub 2022 Jul 13. N Engl J Med. 2022. PMID: 35830649 Clinical Trial.
Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial.
Straus DJ, Długosz-Danecka M, Connors JM, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Ramchandren R, Zinzani PL, Hutchings M, Munoz J, Lee HJ, Kim WS, Advani R, Ansell SM, Younes A, Gallamini A, Liu R, Little M, Fenton K, Fanale M, Radford J. Straus DJ, et al. Among authors: smolewski p. Lancet Haematol. 2021 Jun;8(6):e410-e421. doi: 10.1016/S2352-3026(21)00102-2. Lancet Haematol. 2021. PMID: 34048680 Clinical Trial.
Immune Checkpoint Inhibitors to Treat Malignant Lymphomas.
Witkowska M, Smolewski P. Witkowska M, et al. Among authors: smolewski p. J Immunol Res. 2018 Apr 11;2018:1982423. doi: 10.1155/2018/1982423. eCollection 2018. J Immunol Res. 2018. PMID: 29850620 Free PMC article. Review.
Emerging antibody-drug conjugates for treating lymphoid malignancies.
Wolska-Washer A, Robak P, Smolewski P, Robak T. Wolska-Washer A, et al. Among authors: smolewski p. Expert Opin Emerg Drugs. 2017 Sep;22(3):259-273. doi: 10.1080/14728214.2017.1366447. Epub 2017 Aug 28. Expert Opin Emerg Drugs. 2017. PMID: 28792782 Review.
Clinical management of mantle cell lymphoma in the elderly.
Smolewski P, Rydygier D, Robak T. Smolewski P, et al. Expert Opin Pharmacother. 2019 Oct;20(15):1893-1905. doi: 10.1080/14656566.2019.1642871. Epub 2019 Aug 2. Expert Opin Pharmacother. 2019. PMID: 31373238 Review.
Emerging immunological drugs for chronic lymphocytic leukemia.
Robak P, Smolewski P, Robak T. Robak P, et al. Among authors: smolewski p. Expert Opin Emerg Drugs. 2015 Sep;20(3):423-47. doi: 10.1517/14728214.2015.1046432. Epub 2015 Jul 11. Expert Opin Emerg Drugs. 2015. PMID: 26153226 Review.
127 results